Operating
Edwards Lifesciences·Cash Flow Statement·17 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net income | $365M | $3.1B | $384.3M | $356.4M | $331.5M | $290.3M | $91.2M | $380.7M |
| Change in accounts payable | $151.8M | $29.9M | $0 | -$103.4M | $103.7M | $226.1M | $168.7M | -$347.1M |
| Asset write-downs | $0 | — | — | $0 | $47.1M | — | — | $123.6M |
| Increase (Decrease) in Accounts and Other Receivables | -$23M | -$47.3M | -$105.9M | $43.7M | $24.9M | — | — | $117.9M |
| Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss | — | — | $30.4M | $0 | — | — | $0 | $65.2M |
| Intellectual property agreement accrual | -$6.6M | -$12.5M | -$12.5M | -$36.7M | -$12.5M | -$12.5M | -$14.8M | -$50M |
| Stock-based compensation | $43.9M | $42.1M | $31.7M | $40.2M | $37.5M | $41.2M | $39.2M | $45.4M |
| Net cash from operating activities | $371.5M | $351.8M | — | $280.4M | $290.2M | $573.7M | $450.9M | $43.8M |
| Change in income taxes payable/receivable | -$106.9M | $671.8M | -$488.5M | $51.2M | -$240.4M | -$10.2M | — | $41.9M |
| Depreciation and amortization | $39.6M | $34.5M | $42.6M | $36.6M | $38.1M | $39.2M | $42.7M | $40.9M |
| Other working capital changes | $900K | $0 | $17.3M | $28.6M | — | $7.9M | $2.7M | $18.1M |
| Increase (Decrease) in Deferred Income Taxes | $66.1M | $123M | $98.5M | $24.3M | $20.9M | $18M | $54.4M | -$9.4M |
| Increase (Decrease) in Prepaid Expense and Other Assets | -$13M | — | — | -$10.6M | $13.9M | $14.2M | $6.2M | $8.7M |
| Operating lease right-of-use asset amortization | $7.4M | $6.5M | $6.2M | $6.1M | $6.4M | $6.8M | $6.6M | $6.5M |
| Gain (Loss) on Investments | — | — | — | -$12.5M | — | — | — | -$3.5M |
| Change in inventories | $94.2M | $41.2M | $51.2M | $100K | -$41.6M | $0 | -$11M | $1.6M |
| Other Noncash Income (Expense) | -$1.5M | -$700K | -$10.5M | -$3.6M | -$4.7M | — | -$5.4M | -$500K |